genOway SA

Paris Stock Exchange ALGEN.PA

genOway SA Capital Expenditure for the year ending December 31, 2023: USD -1.97 M

genOway SA Capital Expenditure is USD -1.97 M for the year ending December 31, 2023, a 4.03% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • genOway SA Capital Expenditure for the year ending December 31, 2022 was USD -2.05 M, a 20.83% change year over year.
  • genOway SA Capital Expenditure for the year ending December 31, 2021 was USD -2.59 M, a 53.05% change year over year.
  • genOway SA Capital Expenditure for the year ending December 31, 2020 was USD -5.52 M.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
Paris Stock Exchange: ALGEN.PA

genOway SA

CEO Dr. Alexandre Fraichard
IPO Date May 7, 2007
Location France
Headquarters Technopark 2
Employees 124
Sector Healthcare
Industries
Description

genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.

Similar companies

ALBIO.PA

Biosynex SA

USD 1.18

2.98%

ALERS.PA

Eurobio Scientific SA

USD 26.53

-0.92%

StockViz Staff

February 6, 2025

Any question? Send us an email